ATE556090T1 - Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung - Google Patents

Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung

Info

Publication number
ATE556090T1
ATE556090T1 AT09177387T AT09177387T ATE556090T1 AT E556090 T1 ATE556090 T1 AT E556090T1 AT 09177387 T AT09177387 T AT 09177387T AT 09177387 T AT09177387 T AT 09177387T AT E556090 T1 ATE556090 T1 AT E556090T1
Authority
AT
Austria
Prior art keywords
platele
shortened
growth factor
derived growth
dna coding
Prior art date
Application number
AT09177387T
Other languages
English (en)
Inventor
Ulf Eriksson
Karin Aase
Annica Ponton
Li Xuri
Marko Uutela
Kari Alitalo
Arne Oestman
Carl-Henrik Heldin
Original Assignee
Ludwig Inst Cancer Res
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Licentia Ltd filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE556090T1 publication Critical patent/ATE556090T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
AT09177387T 1998-11-10 1999-11-10 Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung ATE556090T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10785298P 1998-11-10 1998-11-10
US11399798P 1998-12-28 1998-12-28
US15060499P 1999-08-26 1999-08-26
US15710899P 1999-10-04 1999-10-04
US15775699P 1999-10-05 1999-10-05
EP99958854A EP1129110B1 (de) 1998-11-10 1999-11-10 Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen

Publications (1)

Publication Number Publication Date
ATE556090T1 true ATE556090T1 (de) 2012-05-15

Family

ID=27537197

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99958854T ATE451389T1 (de) 1998-11-10 1999-11-10 Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen
AT09177387T ATE556090T1 (de) 1998-11-10 1999-11-10 Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99958854T ATE451389T1 (de) 1998-11-10 1999-11-10 Von blutplättchen abstammender wachstumsfaktor d, dafür kodierende dns und deren verwendungen

Country Status (12)

Country Link
US (1) US6706687B1 (de)
EP (2) EP2151454B1 (de)
JP (1) JP2002534061A (de)
CN (1) CN1261453C (de)
AT (2) ATE451389T1 (de)
AU (1) AU770899B2 (de)
CA (1) CA2349951A1 (de)
DE (1) DE69941791D1 (de)
DK (1) DK1129110T3 (de)
ES (1) ES2336731T3 (de)
NZ (1) NZ511379A (de)
WO (1) WO2000027879A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
JP2002542825A (ja) * 1999-05-03 2002-12-17 ザイモジェネティクス，インコーポレイティド 増殖因子同族体ｚｖｅｇｆ４
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
CA2386383A1 (en) * 1999-10-07 2001-04-12 Curagen Corporation Growth factor polypeptides and nucleic acids encoding same
WO2001089450A2 (en) * 2000-05-19 2001-11-29 Eli Lilly And Company Treating musculoskeletal disorders using lp85 and analogs thereof
DK1355655T5 (da) 2000-10-30 2007-08-13 Zymogenetics Inc Præparater og fremgangsmåder til forbedring af nyrefunktion
AU2002248201A1 (en) * 2000-11-16 2002-08-06 Curagen Corporation Growth factor polypeptides and nucleic acids encoding same
ATE384783T1 (de) * 2001-10-19 2008-02-15 Zymogenetics Inc Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
WO2003068802A2 (en) * 2002-02-11 2003-08-21 Zymogenetics, Inc. Materials and methods for preparing dimeric growth factors
AU2003272547A1 (en) * 2002-09-16 2004-04-30 Abgenix, Inc. Method for the treatment of nephritis using anti-pdgf-dd antibodies
US20030100502A1 (en) * 2002-10-23 2003-05-29 Beals John Michael Treating musculoskeletal disorders using lp85 and analogs thereof
US20050191286A1 (en) * 2004-02-09 2005-09-01 Gandy James B. Lyophilized platelet rich plasma for the use in wound healing (chronic or acute) and bone or tissue grafts or repair
WO2005087177A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
WO2005086684A2 (en) * 2004-03-08 2005-09-22 Ludwig Institute For Cancer Research Method for modulating, regulating and/or stabilizing angiogenesis
US20060142198A1 (en) * 2004-07-02 2006-06-29 Wound Care Partners Llc Compositions for treating wounds and processes for their preparation
US20060004189A1 (en) * 2004-07-02 2006-01-05 James Gandy Compositions for treating wounds and processes for their preparation
EP1885888A4 (de) * 2005-05-10 2010-05-05 Ludwig Inst Cancer Res Verfahren und zusammensetzungen zur aktivierung und hemmung von pdgf-d
AU2006279462A1 (en) 2005-08-15 2007-02-22 Vegenics Limited Modified VEGF and PDGF with improved angiogenic properties
PL2018184T3 (pl) 2006-05-17 2013-12-31 The Ludwig Institute For Cancer Res Przeciwciało Anty-VEGF-B do stosowania w leczeniu lub profilaktyce cukrzycy typu II lub zespołu metabolicznego
AU2010211438B2 (en) * 2009-02-06 2016-04-14 Academisch Ziekenhuis Maastricht Truncated cystine-knot proteins
KR101451340B1 (ko) * 2012-08-02 2014-10-15 (주)애드바이오텍 모발 생장 촉진용 조성물
CN103469672A (zh) * 2013-09-07 2013-12-25 郴州四方立投资有限公司 一种用于造纸行业的硅灰石长纤维的制备方法
AU2016291778B2 (en) * 2015-07-13 2021-05-06 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
CN110590930B (zh) * 2018-06-13 2023-03-31 四川好医生攀西药业有限责任公司 美洲大蠊生长因子pdgf在制备损伤修复药物中的应用
WO2020151666A1 (zh) * 2019-01-25 2020-07-30 四川大学华西医院 血管瘤治疗的生物标记物
CN115612661B (zh) * 2021-07-14 2026-02-13 中山大学中山眼科中心 Pdgf-d在调控干细胞增殖和/或分化中的应用
CN114957439B (zh) * 2022-05-31 2023-11-28 新疆畜牧科学院生物技术研究所（新疆畜牧科学院中国-澳大利亚绵羊育种研究中心） 绵羊pdgfd、编码pdgfd核酸及其重组慢病毒、宿主细胞与应用
WO2024002271A1 (en) * 2022-06-29 2024-01-04 Tianjin University Pdgf-d prodomain and its mutant and fusion
KR20250040765A (ko) * 2023-09-15 2025-03-25 (주)케어젠 펩타이드를 유효성분으로 하는 발모 촉진 또는 탈모증의 억제, 예방 또는 개선용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4228457A1 (de) * 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
US5585277A (en) 1993-06-21 1996-12-17 Scriptgen Pharmaceuticals, Inc. Screening method for identifying ligands for target proteins
EP0751992B1 (de) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5607918A (en) 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
DE69630442T2 (de) * 1995-03-02 2004-08-19 Amrad Operations Pty. Ltd., Richmond Ein neuartiger wachstumsfaktor und eine genetische sequenz, die für diesen codiert
CA2224002A1 (en) 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human vascular endothelial growth factor 3
AU729880C (en) 1996-08-23 2001-11-08 Vegenics Limited Recombinant vascular endothelial cell growth factor D (VEGF-D)
WO2000034474A2 (en) * 1998-12-07 2000-06-15 Zymogenetics, Inc. Growth factor homolog zvegf3
JP2002542825A (ja) * 1999-05-03 2002-12-17 ザイモジェネティクス，インコーポレイティド 増殖因子同族体ｚｖｅｇｆ４

Also Published As

Publication number Publication date
NZ511379A (en) 2003-06-30
ES2336731T3 (es) 2010-04-15
EP1129110A1 (de) 2001-09-05
CN1325407A (zh) 2001-12-05
EP2151454B1 (de) 2012-05-02
AU1613600A (en) 2000-05-29
CA2349951A1 (en) 2000-05-18
EP2151454A3 (de) 2010-02-17
EP2151454A2 (de) 2010-02-10
JP2002534061A (ja) 2002-10-15
CN1261453C (zh) 2006-06-28
DE69941791D1 (de) 2010-01-21
WO2000027879A1 (en) 2000-05-18
US6706687B1 (en) 2004-03-16
EP1129110A4 (de) 2004-08-04
DK1129110T3 (da) 2010-04-06
EP1129110B1 (de) 2009-12-09
AU770899B2 (en) 2004-03-04
ATE451389T1 (de) 2009-12-15

Similar Documents

Publication Publication Date Title
ATE556090T1 (de) Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung
DE3864585D1 (de) Dns-molekule, codierend fuer non-a-non-b-hepatitis-antigene und ihre verwendung zur herstellung dieser antigene.
DE69838592D1 (de) Diacylglyzerin o-acyltransferase
DE60237851D1 (de) Modifiziertes Propylenpolymer, dieses enthaltende Zusammensetzung und deren Verwendung
TR201815552T4 (tr) Agregasyon ile ilgili hastalıkların tedavisine yönelik iyileştirilmiş nanoantikorlar (TM).
SG2013005590A (en) Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
FI875220A7 (fi) Mikrobeja tuhoavia proteiineja, niitä sisältäviä koostumuksia ja niiden käyttö.
BR0211546A (pt) Composição farmacêutica e/ou de diagnóstico e uso de microrganismo ou célula
ATE120219T1 (de) Kombinationen von glycosaminoglycan mit kationischen polymeren.
DE3650751D1 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
DE60042969D1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
DE3855421D1 (de) Modularer Zusammenbau von Antikörpergenen, dadurch hergestellte Antikörper und deren Anwendung
ATE507828T1 (de) Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung
ATE56728T1 (de) Neue polypeptide mit alpha-amylase-hemmender wirkung, verfahren zu deren herstellung, deren verwendung und pharmazeutische praeparate.
FI962247L (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
ATE406448T1 (de) Diacylglycerin o-acyltransferase
ATE130869T1 (de) Protein mit der aktivität vom typ von cytokin, dafür kodierende rekombinante dns, transformierte zellen und mikroorganismen.
DE3581255D1 (de) Dns, deren herstellung und verwendung.
DE68925869D1 (de) Modifizierte Proteine, modifizierte Interferone alpha- und beta-phosphorylierte Proteine, DNA-Sequenzen und Analoge und deren Verwendung
EP1089635A4 (de) Verwendung von oelen mit hohem laurinsaeureanteil als tierfuttermittel
Konradsson et al. Interleukin‐1 levels in gingival crevicular fluid adjacent to restorations of calcium aluminate cement and resin composite
DE69924009D1 (de) Methode zur verstärkung der biologischen aktivität von liganden
DE69839582D1 (de) Neues polypeptid, dafür kodierende dna und deren verwendungen
FI972170A7 (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, n äitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
ATE202570T1 (de) Gene, die für macif proteine kodieren, expressionsvektoren mit diesem genen, und transformantenzellen mit diesem proteinen